权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Fibroblast Mediated Mechanisms of Pulmonary Hypertension

成纤维细胞介导的肺动脉高压机制

基本信息

批准号：
10378641
负责人：
RICHARD D MINSHALL
金额：
$ 39.98万
依托单位：
UNIVERSITY OF ILLINOIS AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-15 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10378641
关键词：
6-Phosphofructo-2-kinase Activin Receptor Address Amplifiers Animal Model BMPR2 gene Blood Vessels Blood capillaries Cell Proliferation Cells Cessation of life Conditioned Culture Media Data Development Diphtheria Toxin Disease Disease Progression Drug Targeting Energy Metabolism Extracellular Matrix Family Fibroblasts Fibrosis Fructose Glycolysis Grant Human Inherited Lead Lesion Lung Measures Mediating Metabolic Metalloproteases Mitogens Modeling Molecular Disease Mus Muscle Mutate Mutation Myofibroblast Pathogenesis Pathogenicity Pathway interactions Patients Perivascular Fibrosis Persons Phenotype Phosphorylation Population Pulmonary Hypertension Pulmonary artery structure RNA analysis Research Research Personnel Role Signal Pathway Signal Transduction Smooth Muscle Testing Therapeutic Translating Trees United States Up-Regulation Vascular Endothelium Vascular Smooth Muscle Work aerobic glycolysis base effective therapy experimental study fibrotic lung disease genetic approach idiopathic pulmonary fibrosis in vivo insight mortality mouse model novel therapeutics paracrine prevent pulmonary arterial hypertension pulmonary function response suicide gene transcriptome sequencing

项目摘要

PROJECT SUMMARY/ABSTRACT Pulmonary arterial hypertension (PAH) is characterized by a severe narrowing of pre-capillary pulmonary arteries due to a combination of increased muscularization and formation of plexiform lesions. PAH has a high mortality rate (15% 1-year mortality) resulting in ~15,000 deaths annually in the United States alone. Mutations in BMPR2 have been identified in >70% of patients with hereditary PAH and also some cases of sporadic PAH; however, no new and fully effective treatments have been developed based on these findings. In the proposed studies, we will focus on understanding the underlying molecular disease mechanisms using a mouse model that expresses a BMPR2 mutation found in a family with hereditary PAH (BMPR2+/R899X mice). The major focus based on exciting supporting data will be to define the potentially important but enigmatic role of fibroblasts as disease amplifiers in BMPR2+/R899X mice. This concept is driven in large measure by observations in patients and animal models of fibrosis localized around the vascular tree and that patients with fibrotic lung disease (such as idiopathic pulmonary fibrosis) also have significantly heightened likelihood of developing PAH. The fundamental question therefore is whether there is a causal relationship between aberrant BMPR2 signaling in pulmonary fibroblasts and the development and progression of PAH. In my first RO1 grant as an independent investigator I will test the hypothesis that BMPR2+/R899X fibroblasts become locked into a hyper-activated and pathogenic state that is crucial for the progression to fulminant disease. To test this hypothesis, I will identify the dysregulated signaling pathways that lead to aberrant fibroblast activation including how a reduction in BMPR2 levels leads to aberrant activation of Activin Receptor 2A (ACVR2A). Further, I will address how fibroblast activation in turn leads to vascular smooth muscle proliferation and thereby contributes to PAH. In response to the previous concerns we have thoroughly revised the proposal and provide new data showing feasibility and potential importance of the work. The intent ultimately will be that through the insights gained we can translate these findings into new therapies by defining previously unknown signaling pathways and anti-PAH drug targets.

项目总结/文摘